Key result
Calycosin reduces doxorubicin-induced cardiotoxicity in preclinical models via the Sirt1-NLRP3 pathway.
Why the study?
Doxorubicin-induced cardiotoxicity is a vital clinical problem limiting its use, and the protective effects and mechanisms of calycosin against this toxicity require investigation.
Does calycosin ameliorate doxorubicin-induced cardiotoxicity in preclinical models?
Population
H9c2 cells and mice with doxorubicin-induced cardiotoxicity
Comparison
Calycosin treatment versus doxorubicin alone
Design
Preclinical in vitro and in vivo experimental study
Authors
Loading...
CA may attenuate DOX cardiotoxicity in models; leaves open clinical translation and safety in patients.
Does calycosin ameliorate doxorubicin-induced cardiotoxicity in preclinical models?
Calycosin ameliorates doxorubicin-induced cardiotoxicity in preclinical models by suppressing oxidative stress and inflammation via the Sirt1-NLRP3 pathway.
Zhai et al. (2019) studied Doxorubicin-induced cardiotoxicity. Calycosin vs. Doxorubicin alone was evaluated on Cardiotoxicity (cell viability, apoptosis, oxidative stress). Calycosin ameliorated doxorubicin-induced cardiotoxicity in vitro and in vivo by suppressing oxidative stress and inflammation via the Sirt1-NLRP3 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: